The GLP-1 Era Matures: Oral Pills, Surgery Timing, and an Addiction Crossover

Start with the cleanest of the four findings. The SEMA-TR study followed 500 adults with type 2 diabetes in the Çukurova region of Türkiye who initiated semaglutide between 2024 and 2025, grouped by the maximum dose they tolerated: 0.25 mg, 0.50 mg, or 1.00 mg. Over 30 weeks, the overall mean HbA1c reduction was 1.03 percentage points — a meaningful drop in a real clinic, not a tightly controlled trial. The dose-response was clean: roughly 0.72, 1.02, and 1.27 percentage points across the three groups, with insulin-dose reductions becoming more frequent as patients climbed the ladder (40%, 41%, and 51%).

That is the part that will get quoted. The part that should get quoted alongside it: 117 of the 500 patients — 23.4% — discontinued therapy. Real-world means real attrition. Gym-floor translation: the people who tolerate the climb to the higher doses get bigger results, but a non-trivial slice never gets there. The dose is doing work. So is patient selection.

Oral semaglutide was the first oral GLP-1 receptor agonist approved for type 2 diabetes, and the new evidence-informed clinical guidance from Rubino and colleagues walks through its expanded role in obesity management and cardiovascular risk reduction. The authors describe weight loss comparable to subcutaneous GLP-1 therapies, alongside improvements in cardiometabolic risk factors. That is the headline. The fine print is the administration protocol, and it is genuinely strict.

To absorb properly, oral semaglutide has to be taken first thing in the morning, on an empty stomach, with no more than half a glass of plain water — up to 120 mL, roughly four fluid ounces — and then nothing else for 30 minutes. No food, no coffee, no other pills, no protein shake on the way to the gym. The guidance leans hard on person-centered conversations before initiation: realistic expectations, adverse-event preparation, and an honest look at whether a patient's morning routine can actually accommodate the protocol. The pill is real. The discipline it demands is real too.

If you or someone in your training group is on a GLP-1 and considering a body-contouring procedure after weight loss, the retrospective study by Agostino and colleagues is the one to read. Eighty patients undergoing primary lipoabdominoplasty were divided into four matched groups: semaglutide continued until surgery, two-week discontinuation, four-week discontinuation, and semaglutide-naïve controls. Thirty-day complication rates told a steep story — 45% in the continuation group, 30% at two weeks, 10% at four weeks, and 10% in the controls. The reported complications included wound dehiscence, infection, and seroma formation, with more gastrointestinal intolerance and longer drain duration in patients with ongoing semaglutide use. No reoperations or readmissions occurred.

This is a single retrospective study of 80 patients at one institution — not a verdict. But the gradient is hard to ignore, and it lines up with the broader peri-operative concern about delayed gastric emptying on GLP-1 therapy. The practical read: anyone with semaglutide on board and elective surgery on the calendar needs that conversation with their surgeon and prescriber early, not the week before.

The fourth strand is the most speculative and the most fascinating. An exploratory retrospective cohort study by Qeadan and colleagues, drawing on de-identified records from 149 U.S. health systems between 2014 and 2024, looked at 107,217 patients aged 12 and older with co-occurring opioid and alcohol use disorders. Using marginal structural survival models with stabilized inverse probability weighting, the authors estimated that GIP/GLP-1 receptor agonist prescriptions were associated with a lower risk of all-drug overdose among patients not receiving first-line medications for opioid or alcohol use disorder — an adjusted hazard ratio of 0.61 (95% CI 0.32–0.98).

Read that sentence twice. It is an exploratory association in a stratified subgroup of a retrospective EHR cohort. The authors frame it that way deliberately. It is not evidence that GLP-1s treat addiction, and it should not be used to justify off-label prescribing. What it is: a signal worth following with prospective work, in a clinical area — co-occurring substance use disorders — where existing medications are chronically underused. File it under watch this space.

The throughline across all four studies is the same: this drug class works, and it has edges. The edges are where the next two years of evidence are going to live — dosing strategy, formulation choice, peri-operative protocols, and the genuinely novel question of whether GLP-1 biology touches reward circuitry in ways that matter clinically. None of that requires hype to be interesting. It just requires reading carefully. If you are a candidate for one of these medications, the conversation to have with your clinician in 2026 is not should I try this. It is how do we use it well, and for how long, and what's the off-ramp. That is what a mature drug class looks like.